Shares of Pro Medicus Limited (OTCMKTS:PMCUF – Get Free Report) saw an uptick in trading volume on Wednesday . Approximately 2,022 shares were traded during mid-day trading, an increase of 239% from the previous session’s volume of 596 shares.The stock last traded at $120.00 and had previously closed at $119.31.
Analyst Upgrades and Downgrades
Separately, Jefferies Financial Group downgraded shares of Pro Medicus from a “buy” rating to a “hold” rating in a report on Wednesday, July 8th. One analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $155.00.
Read Our Latest Stock Analysis on Pro Medicus
Pro Medicus Stock Performance
About Pro Medicus
Pro Medicus Limited is an Australian medical technology company that develops software for medical imaging and radiology. Its principal platform, Visage 7, is an enterprise imaging solution designed to help healthcare organizations store, access, interpret and distribute large volumes of medical images.
Visage 7 supports radiology workflows across modalities such as computed tomography, magnetic resonance imaging and digital X-ray. The platform includes tools for image visualization, clinical review, collaboration and integration with hospital information systems, with an emphasis on fast access to imaging data and streamlined diagnostic workflows.
Founded in Melbourne in 1983, Pro Medicus serves hospitals, imaging networks and other healthcare providers in Australia, North America and Europe.
Featured Stories
- Five stocks we like better than Pro Medicus
- Feed to Feat: Can Meta Unlock the AI Agent Cash Machine?
- Chime Finds Its Stride With a $590M Deal That Could Reshape Its Banking Model
- IBM and Lockheed Martin Turn a Swiss Defense Deal Into a Quantum Computing Bet
- AeroVironment’s Record Backlog and Earnings Beat Fuel Recovery Case
Receive News & Ratings for Pro Medicus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pro Medicus and related companies with MarketBeat.com's FREE daily email newsletter.
